Disrupted in Renal Carcinoma 2 (DIRC2) (Middle Region) Peptide
DIRC2
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN975800
Aperçu rapide pour Disrupted in Renal Carcinoma 2 (DIRC2) (Middle Region) Peptide (ABIN975800)
Antigène
DIRC2
(Disrupted in Renal Carcinoma 2 (DIRC2))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
Protein Region
Middle Region
Attributs du produit
This is a synthetic peptide designed for use in combination with anti-DIRC2 antibody (Catalog #: ARP50133_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Concentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Conseil sur la manipulation
Avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Antigène
DIRC2
(Disrupted in Renal Carcinoma 2 (DIRC2))
Sujet
DIRC2 is a membrane-bound protein from the major facilitator superfamily of transporters. Disruption of DIRC2 by translocation has been associated with haplo-insufficiency and renal cell carcinomas. Alternatively spliced transcript variants have been described, but their biological validity has not yet been determined.This gene encodes a membrane-bound protein from the major facilitator superfamily of transporters. Disruption of this gene by translocation has been associated with haplo-insufficiency and renal cell carcinomas. Alternatively spliced transcript variants have been described, but their biological validity has not yet been determined. Sequence Note: The RefSeq transcript and protein were derived from genomic sequence and transcripts to make the sequence consistent with the reference genome assembly. The genomic coordinates used for the transcript record were based on alignments.